Yongjun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yongjun Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bingyan Guo
The Second Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publicationGuo‐Zhen Hao
Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
1 shared publication- Jing Li
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
1 shared publication Li Qiao
The Second Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publicationLiang Chang
The Second Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publicationMengnan Sun
Department of Clinical and Registration Affairs, Beijing Sanhe Dingye Technology Co., Ltd, Beijing, China
1 shared publication
Latest Publications
- Open Access
Efficacy and safety of endovenous microwave ablation versus laser ablation for great saphenous vein varicosis: study protocol for a multicentre, randomised controlled non-inferiority trial
Introduction Endovenous microwave ablation (EMA) is a relatively novel thermal ablation treatment for great saphenous vein (GSV) varicosis, and its efficacy and safety are rarely reported. This study aims to explore whether EMA can be comparable to endovenous laser ablation (EVLA), which is a widely used thermal ablation treatment in clinical practice. Methods and analysis This is a multicentre, randomised controlled non-inferiority trial to compare the efficacy and safety of EMA and EVLA in patients with GSV varicosis. We will recruit 180 patients in 6 centres and randomly assign them into treatment group (EMA group) and control group (EVLA group) in a 1:1 ratio. The patients will return to the hospitals at 7 days, 3 months, 6 months and 12 months, and will be called at 1 month after the treatment for follow-up visits. The primary outcome is the occlusion rate of GSV immediately, at 6 months, and at 12 months after the treatment. The secondary outcomes are Venous Clinical Severity Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ) Score, operation time and instrument performance evaluation. Ethics and dissemination This protocol has been approved by the Clinical Trial Ethics Committee of Beijing Hospital (2020BJYYEC-126–02), Peking Union Medical College Hospital (KS2020393), Beijing Tsinghua Changgung Hospital (No.20279-2-02), Beijing Luhe Hospital.Capital Medical University (2020-LHYW-030–01), the First Hospital of Hebei Medical University (No.2020249), and the First Affiliated Hospital of Xi’an Jiaotong University (XJTU1AF2021LSY-12). The trial results will be published in peer-reviewed journals. Trial registration number NCT04726124.
Open AccessEfficacy and safety of endovenous microwave ablation versus laser ablation for great saphenous vein varicosis: study protocol for a multicentre, randomised controlled non-inferiority trial
Introduction Endovenous microwave ablation (EMA) is a relatively novel thermal ablation treatment for great saphenous vein (GSV) varicosis, and its efficacy and safety are rarely reported. This study aims to explore whether EMA can be comparable to endovenous laser ablation (EVLA), which is a widely used thermal ablation treatment in clinical practice. Methods and analysis This is a multicentre, randomised controlled non-inferiority trial to compare the efficacy and safety of EMA and EVLA in patients with GSV varicosis. We will recruit 180 patients in 6 centres and randomly assign them into treatment group (EMA group) and control group (EVLA group) in a 1:1 ratio. The patients will return to the hospitals at 7 days, 3 months, 6 months and 12 months, and will be called at 1 month after the treatment for follow-up visits. The primary outcome is the occlusion rate of GSV immediately, at 6 months, and at 12 months after the treatment. The secondary outcomes are Venous Clinical Severity Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ) Score, operation time and instrument performance evaluation. Ethics and dissemination This protocol has been approved by the Clinical Trial Ethics Committee of Beijing Hospital (2020BJYYEC-126–02), Peking Union Medical College Hospital (KS2020393), Beijing Tsinghua Changgung Hospital (No.20279-2-02), Beijing Luhe Hospital.Capital Medical University (2020-LHYW-030–01), the First Hospital of Hebei Medical University (No.2020249), and the First Affiliated Hospital of Xi’an Jiaotong University (XJTU1AF2021LSY-12). The trial results will be published in peer-reviewed journals. Trial registration number NCT04726124.
- Open Access
- 15 February 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (S1) , 839-845
Comparison of myocardial microcirculatory perfusion after catheter‐administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST‐elevation myocardial infarction
Objective: To evaluate efficacy, safety and feasibility of targeted intracoronary injection using pro‐urokinase combined with anisodamine (TCA) versus thrombus aspiration (TA) in ST‐elevation myocardial infarction (STEMI) patients with high thrombus loads.Background: The best method of avoiding thrombus detachment and stroke in PCI patients with high thrombus loads has not yet been established.Methods: STEMI patients receiving coronary artery angiography or percutaneous coronary intervention (CAG/PCI) with thrombus grade ≥ 3 from January 1, 2017 to June 30, 2018 were randomly assigned to targeted intracoronary thrombolysis (pro‐urokinase and anisodamine via catheter (TCA) group), or the TA group which followed the standard thrombus aspiration procedure. Parameters compared included thrombus grade, index of microcirculatory resistance (IMR), postoperative myocardial SPECT, thrombosis in myocardial infarction (TIMI) scores including flow grade, corrected TIMI frame counts (CTFCs), and TIMI myocardial perfusion grade (TMPG). Adverse events were followed up within 3 months.Results: Thirty‐nine patients were finally enrolled. In primary CAG/PCI, the TCA group had higher percentages of TIMI 3 flow and lower IMR values compared with the TA group. The ratio of TMPG 3 grade in the TCA group was higher in repeat CAG, and the perfusion descending area (PDA) presented by SPECT was lower than in the TA group. No significant difference was seen in major adverse coronary events (MACEs) or bleeding events at follow‐up.Conclusions: TCA appears to be effective, safe, and feasible for repatency and reduction of high thrombus burden in primary PCI and may protect myocardial microcirculation with improved outcomes.
- 15 February 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (S1) , 839-845
Open AccessComparison of myocardial microcirculatory perfusion after catheter‐administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST‐elevation myocardial infarction
Objective: To evaluate efficacy, safety and feasibility of targeted intracoronary injection using pro‐urokinase combined with anisodamine (TCA) versus thrombus aspiration (TA) in ST‐elevation myocardial infarction (STEMI) patients with high thrombus loads.Background: The best method of avoiding thrombus detachment and stroke in PCI patients with high thrombus loads has not yet been established.Methods: STEMI patients receiving coronary artery angiography or percutaneous coronary intervention (CAG/PCI) with thrombus grade ≥ 3 from January 1, 2017 to June 30, 2018 were randomly assigned to targeted intracoronary thrombolysis (pro‐urokinase and anisodamine via catheter (TCA) group), or the TA group which followed the standard thrombus aspiration procedure. Parameters compared included thrombus grade, index of microcirculatory resistance (IMR), postoperative myocardial SPECT, thrombosis in myocardial infarction (TIMI) scores including flow grade, corrected TIMI frame counts (CTFCs), and TIMI myocardial perfusion grade (TMPG). Adverse events were followed up within 3 months.Results: Thirty‐nine patients were finally enrolled. In primary CAG/PCI, the TCA group had higher percentages of TIMI 3 flow and lower IMR values compared with the TA group. The ratio of TMPG 3 grade in the TCA group was higher in repeat CAG, and the perfusion descending area (PDA) presented by SPECT was lower than in the TA group. No significant difference was seen in major adverse coronary events (MACEs) or bleeding events at follow‐up.Conclusions: TCA appears to be effective, safe, and feasible for repatency and reduction of high thrombus burden in primary PCI and may protect myocardial microcirculation with improved outcomes.
- Open Access
- 11 October 2017
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (1) , 382-389
Integrin β‐3 is required for the attachment, retention and therapeutic benefits of human cardiospheres in myocardial infarction
Cardiovascular diseases remain the leading causes of death worldwide. Stem cell therapy offers a promising option to regenerate injured myocardium. Among the various types of stem cells, cardiosphere cells represent a mixture of intrinsic heart stem cells and supporting cells. The safety and efficacy of cardiosphere cells have been demonstrated in recent clinical trials. Cell–matrix interaction plays an important role in mediating the engraftment of injected stem cells. Here, we studied the role of integrin β‐3 in cardiosphere‐mediated cell therapy in a mouse model of myocardial infarction. Our results indicated that inhibiting integrin β‐3 reduced attachment, retention and therapeutic benefits of human cardiospheres in mice with acute myocardial infarction. This suggests integrin β‐3 plays an important role in cardiosphere‐mediated heart regeneration.
- 11 October 2017
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (1) , 382-389
Open AccessIntegrin β‐3 is required for the attachment, retention and therapeutic benefits of human cardiospheres in myocardial infarction
Cardiovascular diseases remain the leading causes of death worldwide. Stem cell therapy offers a promising option to regenerate injured myocardium. Among the various types of stem cells, cardiosphere cells represent a mixture of intrinsic heart stem cells and supporting cells. The safety and efficacy of cardiosphere cells have been demonstrated in recent clinical trials. Cell–matrix interaction plays an important role in mediating the engraftment of injected stem cells. Here, we studied the role of integrin β‐3 in cardiosphere‐mediated cell therapy in a mouse model of myocardial infarction. Our results indicated that inhibiting integrin β‐3 reduced attachment, retention and therapeutic benefits of human cardiospheres in mice with acute myocardial infarction. This suggests integrin β‐3 plays an important role in cardiosphere‐mediated heart regeneration.